Designed Ankyrin Repeat Protein (darpin) to Target Chimeric Antigen Receptor (Car)-Redirected T Cells Towards CD4+ T Cells to Reduce the Latent HIV+ Cell Reservoir.

Chimeric Antigen Receptor (CAR)-redirected T cells show great efficacy in the patient-specific therapy of hematologic malignancies. Here, we demonstrate that a DARPin with specificity for CD4 specifically redirects and triggers the activation of CAR engineered T cells resulting in the depletion of CD4+ target cells aiming for elimination of the human immunodeficiency virus (HIV) reservoir.